SMi Pain Therapeutics overview
London, UK, 14 May 2019. The SMi Pain Therapeutics Congress of 14-15 May 2019 is taking place under the co-chairmanships of Kerrie Brady, Chief Business Officer of Centrexion Therapeutics Corp. (Boston, MA) and Michael Scherz, Founder & CEO of Metys Pharmaceuticals AG (Basel, Switzerland).
The co-chairs welcomed participants to the conference with the following joint statement:
"Dear Colleagues,
It has been a memorable year for the global pain drug development community. The first regulatory approvals for CGRP migraine drugs in the US and Europe have ushered in a novel pharmacological strategy for treating and preventing migraine. On the other hand, Nav1.7 inhibitors had signifi cant challenges in their clinical development, as clinical trial results have been less than encouraging. The FDA have awarded, for the first time ever, the Breakthrough designation to promising new pain drugs; and the Agency has promised new guidelines that govern the development of novel therapeutics options for the treatment of pain. The US National Institutes of Health have received $500M in additional funding to facilitate the development of new approaches to pain drug development.
Pain management is a global concern: the European Horizon 2020 “Towards Transatlantic Co-operation in Pain Research” meeting between leading researchers, clinicians, patient groups and government agencies has recommended collaboration priorities for the EU and North America in research on pain and to accelerate access to better and safer pain treatments. Clearly, major changes and challenges are afoot in the novel pain therapeutics ecosystem. Will they make a difference in how we develop new analgesic therapies? Will they lead to new treatments for patients?
The 19th SMi Conference on Pain Therapeutics promises a timely review of promising new therapies and a survey of the breakthroughs and breakdowns of the past year. New clinical trial methodologies will be discussed. Progress from ongoing development efforts will be reported. Interactive round table discussions will allow us all to participate and learn from each other. We’ll refresh our collegial connections and friendships. Join us for a stimulating series of presentations by leaders in our growing fi eld of novel pain therapeutics.
We look forward to welcoming you in London in May 2019."
Kerrie Brady Michael Scherz, PhD
Chief Business Officer Founder & CEO
Centrexion Therapeutics Metys Pharmaceuticals